Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Subscribe To Our Newsletter & Stay Updated